These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 26341251)

  • 1. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
    Kamei K; Ogura M; Sato M; Sako M; Iijima K; Ito S
    Pediatr Nephrol; 2016 Jan; 31(1):89-95. PubMed ID: 26341251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
    Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
    Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
    BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
    Huang J; Du J; Wang S; Xiao L; Zhao X
    Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study.
    Takahashi T; Okamoto T; Sato Y; Yamazaki T; Hayashi A; Aoyagi H; Ueno M; Kobayashi N; Uetake K; Nakanishi M; Ariga T
    Pediatr Nephrol; 2019 Jan; 34(1):87-96. PubMed ID: 30141179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
    Ito S; Kamei K; Ogura M; Udagawa T; Fujinaga S; Saito M; Sako M; Iijima K
    Pediatr Nephrol; 2013 Feb; 28(2):257-64. PubMed ID: 23052656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
    Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome.
    Hogan J; Dossier C; Kwon T; Macher MA; Maisin A; Couderc A; Niel O; Baudouin V; Deschênes G
    Pediatr Nephrol; 2019 Feb; 34(2):253-259. PubMed ID: 30109447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic rituximab administration in children with complicated nephrotic syndrome.
    Okutsu M; Kamei K; Sato M; Kanamori T; Nishi K; Ishiwa S; Ogura M; Sako M; Ito S; Ishikura K
    Pediatr Nephrol; 2021 Mar; 36(3):611-619. PubMed ID: 32995922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome.
    Iijima K; Sako M; Oba M; Tanaka S; Hamada R; Sakai T; Ohwada Y; Ninchoji T; Yamamura T; Machida H; Shima Y; Tanaka R; Kaito H; Araki Y; Morohashi T; Kumagai N; Gotoh Y; Ikezumi Y; Kubota T; Kamei K; Fujita N; Ohtsuka Y; Okamoto T; Yamada T; Tanaka E; Shimizu M; Horinochi T; Konishi A; Omori T; Nakanishi K; Ishikura K; Ito S; Nakamura H; Nozu K;
    J Am Soc Nephrol; 2022 Feb; 33(2):401-419. PubMed ID: 34880074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term prognosis of patients with steroid-dependent nephrotic syndrome treated with rituximab].
    Kamei K; Okada M; Miyazono A; Sato M; Fujimaru T; Ogura M; Ito S
    Nihon Jinzo Gakkai Shi; 2013; 55(5):947-55. PubMed ID: 23980480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel use of rituximab for steroid-dependent nephrotic syndrome in children.
    Kimata T; Hasui M; Kino J; Kitao T; Yamanouchi S; Tsuji S; Kaneko K
    Am J Nephrol; 2013; 38(6):483-8. PubMed ID: 24296765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.
    Ravani P; Magnasco A; Edefonti A; Murer L; Rossi R; Ghio L; Benetti E; Scozzola F; Pasini A; Dallera N; Sica F; Belingheri M; Scolari F; Ghiggeri GM
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1308-15. PubMed ID: 21566104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
    Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
    Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome.
    Wang J; Mao J; Chen J; Fu H; Shen H; Zhu X; Liu A; Shu Q; Du L
    Nephrology (Carlton); 2016 Jan; 21(1):21-7. PubMed ID: 26697959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiopathic nephrotic syndrome and rituximab: may we predict circulating B lymphocytes recovery?
    Delbet JD; Leclerc G; Ulinski T
    Pediatr Nephrol; 2019 Mar; 34(3):529-532. PubMed ID: 30542932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery.
    Sellier-Leclerc AL; Baudouin V; Kwon T; Macher MA; Guérin V; Lapillonne H; Deschênes G; Ulinski T
    Nephrol Dial Transplant; 2012 Mar; 27(3):1083-9. PubMed ID: 21810762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children.
    Basu B; Babu BG; Mahapatra TK
    Clin Exp Nephrol; 2017 Feb; 21(1):143-151. PubMed ID: 27108294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.
    Guigonis V; Dallocchio A; Baudouin V; Dehennault M; Hachon-Le Camus C; Afanetti M; Groothoff J; Llanas B; Niaudet P; Nivet H; Raynaud N; Taque S; Ronco P; Bouissou F
    Pediatr Nephrol; 2008 Aug; 23(8):1269-79. PubMed ID: 18465150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of discontinuing immunosuppression in children with idiopathic nephrotic syndrome.
    Sobue Y; Nishi K; Kamei K; Inoki Y; Osaka K; Kaneda T; Akiyama M; Sato M; Ogura M; Ishikura K; Ishiguro A; Ito S
    Pediatr Nephrol; 2024 Jun; 39(6):1825-1835. PubMed ID: 38270600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.